- 01Screens vs confirmers
ANA and rheumatoid factor are sensitive screens that are positive in many healthy people, so they matter most when negative. Anti-CCP, anti-dsDNA and anti-Sm are specific confirmers that rarely turn positive without disease, so they matter most when positive. Both kinds depend on why the test was ordered: the same positive moves the odds a long way with matching symptoms and very little without them.
A positive autoantibody test shifts the odds of an autoimmune disease, and how far depends on whether the test is a sensitive screen (positive in many healthy people) or a specific confirmer (rarely positive without disease), and on why it was ordered. An autoantibody is an antibody your immune system makes against your own cells or proteins, and the test measures whether one is circulating in your blood. Lupus, rheumatoid arthritis and celiac disease are diagnosed by a rheumatologist or gastroenterologist from symptoms, an exam and several results together, never from one antibody alone. This guide explains how these tests work in general; it cannot tell you what your own result means, so review your result with the clinician who ordered it.
Sensitivity, specificity and the question behind the test
Two numbers describe how any antibody test behaves. Sensitivity is how often the test is positive in people who have the disease; a test with 98% sensitivity catches 98 of every 100 people with the disease. Specificity is how often the test stays negative in people who do not have the disease; a test with 95% specificity wrongly flags 5 of every 100 people without it. Labs set the positive cutoff for a screening test low on purpose so it misses almost nobody, and that choice guarantees some false positives (our guide to reference ranges explains how those cutoffs are drawn).
The third ingredient is pretest probability: how likely the disease was before the blood was drawn, based on your symptoms, exam, age, sex and family history. A positive antibody test in someone with swollen joints, a facial rash and protein in the urine moves the odds a long way. The same positive antibody test in someone with no symptoms, tested as part of a broad workup, moves the odds very little, because the disease was so unlikely to begin with that most positives in that group are false alarms.
Which kind of test gave you a positive?
About 1 in 3 healthy adults has a positive ANA at 1:40 and about 1 in 20 at 1:160, so a low-titer positive ANA with no symptoms is usually not a sign of disease (Tan et al., 1997).
Lupus is rare, so the ANA arithmetic tilts heavily toward healthy people. If 1,000 adults with no symptoms had an ANA checked, roughly 300 would test positive at 1:40 in the Tan data 1, and almost all of those 300 would never develop lupus. A negative ANA, on the other hand, is reassuring: the 2019 lupus classification criteria from EULAR and the American College of Rheumatology (ACR) require an ANA of at least 1:80 before anyone can be classified as having lupus, because ANA at 1:80 or higher is about 98% sensitive for the disease 2.
Why antibodies can show up years before symptoms
Arbuckle and colleagues tested blood samples the US military had stored from 130 service members who were later diagnosed with lupus, and found that autoantibodies appeared before diagnosis in 88% of them, a mean of about 3.3 years and as long as 9.4 years before 4. ANA tended to appear first, with more specific antibodies such as anti-dsDNA arriving closer to the onset of symptoms 4. That timeline explains why a clinician may ask someone with a positive antibody and no symptoms to report new symptoms promptly rather than starting treatment: the antibody can be an early signal, and in many people it never progresses to disease.
What each autoimmune antibody test is for
| Test | Role | Mainly points toward | Read more |
|---|---|---|---|
| ANA (antinuclear antibody) | Screen | Lupus, Sjögren's disease (dry eyes and mouth), scleroderma (skin and tissue hardening) and related connective tissue diseases (conditions where the immune system targets skin, joints and organs) | ANA |
| Anti-dsDNA (double-stranded DNA antibody) | Confirmer | Lupus, including lupus kidney disease | Anti-dsDNA |
| Anti-Sm (anti-Smith antibody) | Confirmer | Found almost only in lupus | ANA |
| Anti-SSA/SSB (Ro and La antibodies) | Targeted follow-up after a positive ANA | Sjögren's disease, some lupus; relevant in pregnancy | Anti-SSA/SSB |
| Rheumatoid factor (RF) | Screen | Rheumatoid arthritis; also positive in some healthy older adults and in other conditions | Rheumatoid factor |
| Anti-CCP (anti-cyclic citrullinated peptide) | Confirmer | Rheumatoid arthritis, often before joints are damaged | Anti-CCP |
| ANCA (anti-neutrophil cytoplasmic antibody) | Targeted test for suspected vasculitis | Vasculitis (inflamed small blood vessels) affecting kidneys, lungs, sinuses | ANCA |
| tTG-IgA (tissue transglutaminase IgA) | First-line test (specific); a positive is usually confirmed by biopsy in adults | Celiac disease | tTG-IgA |
| Complement C3 and C4 | Activity marker (immune proteins, not antibodies) | Low levels can signal active lupus | C3, C4 |
| Total IgA, IgG, IgM (immunoglobulins) | Background check on antibody production | Total IgA is needed to trust a negative tTG-IgA | IgA, IgG, IgM |
How accurate the main tests are
| Test | Sensitivity (catches the disease) | Specificity (stays negative without it) | How to read it |
|---|---|---|---|
| ANA at 1:80 or higher, for lupus | About 98% | Low; positive in about 13% of healthy people at 1:80 | A negative makes lupus very unlikely; a positive needs context 1 2 |
| Rheumatoid factor (IgM type, the one most labs report), for rheumatoid arthritis | About 69% | About 85% | Positive in roughly 15 of every 100 people without RA 3 |
| Anti-CCP, for rheumatoid arthritis | About 67% | About 95% | A positive is strong evidence for RA; a negative does not rule it out 3 |
| Anti-dsDNA or anti-Sm, for lupus | Lower than ANA; many people with lupus test negative | High; rarely positive without lupus | A positive is one of the strongest lupus signals in the 2019 lupus criteria; a negative does not rule lupus out 2 |
| tTG-IgA, for celiac disease | High, if eating gluten and total IgA is normal | High | The ACG's preferred single blood test for celiac disease after age 2; in adults a positive is usually confirmed by biopsy 6 |
Rheumatoid factor and anti-CCP are often ordered together for joint symptoms. In the Nishimura meta-analysis, the two tests caught a similar share of people with rheumatoid arthritis (about 69% for rheumatoid factor and 67% for anti-CCP), but anti-CCP produced far fewer false positives, with specificity of about 95% against about 85% for rheumatoid factor 3. A person who is positive on both has a stronger signal than a person positive on rheumatoid factor alone.
The celiac test has its own conditions
The American College of Gastroenterology (ACG) recommends tTG-IgA, drawn while the person is still eating gluten, as the preferred single test for celiac disease in anyone over age 2, with total IgA checked alongside it 6. A negative tTG-IgA can be falsely reassuring in two situations: if your body makes little IgA overall (checked with a total IgA test), or if you had already cut down on gluten before the blood draw. In adults, a positive tTG-IgA is usually confirmed with an endoscopy and small-bowel biopsy, taken while you are still eating gluten, before celiac disease is diagnosed 6. The tTG-IgA guide covers both situations in detail.
A negative tTG-IgA only rules celiac disease down if total IgA is normal and you were still eating gluten when the blood was drawn.
Inflammation markers are a different question
CRP (C-reactive protein) and ESR (erythrocyte sedimentation rate) measure how much inflammation is in the body right now, from any cause, including infection, injury and autoimmune disease. CRP and ESR do not tell you whether the immune system is targeting your own tissue, so a raised CRP is not an autoimmune result and a normal CRP does not rule autoimmunity out. Our guide to inflammation markers explains those tests.
The ANA-first cascade
Rheumatologists test in a sequence, starting from symptoms and narrowing down, because a broad panel ordered on someone with no symptoms produces a pile of low-value positives. The ACR put the rule plainly in its Choosing Wisely list.
Don't test ANA sub-serologies without a positive ANA and clinical suspicion of immune-mediated disease.American College of Rheumatology, Choosing Wisely, 2013 5
- 1Symptoms and an exam come firstJoint swelling, a rash, dry eyes and mouth, gut symptoms or kidney findings decide which disease is being considered and which test fits the question.
- 2A screening or matched first-line testFor suspected lupus or a connective tissue disease, ANA. For inflammatory joint pain, rheumatoid factor and anti-CCP. For suspected celiac disease, tTG-IgA with total IgA.
- 3Targeted antibodies only if the screen is positive and symptoms fitA positive ANA with matching symptoms can lead to anti-dsDNA, anti-Sm and anti-SSA/SSB, plus complement C3 and C4. Ordering these without a positive ANA adds false positives 5.
- 4A specialist puts it togetherA rheumatologist or gastroenterologist combines the antibody results with the exam, other labs (blood count, kidney function, urine) and sometimes a biopsy or imaging before naming any diagnosis.
Practical questions: fasting, cost and retesting
- Fasting: autoimmune antibody tests do not need fasting. The one dietary condition that matters is for tTG-IgA, which needs you to be eating gluten when the blood is drawn 6.
- Ordering: each antibody is a separate test that has to be requested by name; a standard checkup panel does not include ANA, rheumatoid factor, anti-CCP or tTG-IgA. Labs use different methods to run ANA, and results can differ between them, so compare repeat results from the same lab where possible; the ANA guide explains the methods.
- Cost: in the US, coverage depends on your plan and on why the test was ordered. Tests a clinician orders for symptoms are more often covered than tests ordered with no symptoms, so check with your insurer before testing if cost matters to you.
- Retesting ANA: once an ANA is positive, clinicians generally do not repeat it to watch the titer, because a change in ANA titer is not used to measure how active a disease is. For why one reading rarely tells the whole story, see why trends beat single readings.
- Retesting in lupus: anti-dsDNA levels and complement C3 and C4 can move with lupus activity, so rheumatologists do recheck those in people already diagnosed. Low C3 or C4 (immune proteins that get used up when lupus is active) can be a sign of a flare.
- Retesting in celiac disease: after diagnosis, tTG-IgA is rechecked to confirm the gluten-free diet is working 6, and on a strict gluten-free diet it usually falls toward normal over months to a couple of years.
- Knock-on effects of celiac disease: untreated celiac disease can show up first as low iron or low B12 on routine blood work; see iron deficiency, B12 deficiency and anemia.
- Family members: celiac disease runs in families, and the ACG guideline supports offering testing to first-degree relatives (parents, siblings, children) of people with celiac disease 6.
For a general method you can apply to any number on a lab portal, see how to read any lab result. The autoimmune topic hub gathers every antibody page in one place, and the gut topic hub collects the celiac-related tests. Thyroid antibodies (often behind an underactive thyroid) are covered in how to read your thyroid panel and hypothyroidism; allergy IgE tests are a separate question covered on the total IgE page.

Citations
- Tan EM et al. Range of antinuclear antibodies in healthy individuals. Arthritis Rheum. 1997;40(9):1601-11
- Aringer M et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol. 2019;71(9):1400-12
- Nishimura K et al. Meta-analysis: diagnostic accuracy of anti-cyclic citrullinated peptide antibody and rheumatoid factor for rheumatoid arthritis. Ann Intern Med. 2007;146(11):797-808
- Arbuckle MR et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med. 2003;349:1526-33
- American College of Rheumatology. Choosing Wisely: Five Things Physicians and Patients Should Question (2013)
- Rubio-Tapia A et al. ACG Clinical Guideline: Diagnosis and Management of Celiac Disease. Am J Gastroenterol. 2023;118(1):59-76
Educational context only, not medical advice or a diagnosis. Always discuss your results with a clinician.